Core Viewpoint - The eleventh batch of national organized drug procurement has been announced, including 55 commonly used drugs across various fields, achieving the goals of stabilizing clinical use, ensuring quality, preventing internal competition, and avoiding collusion [1][2] Group 1: Procurement Details - The procurement includes drugs for infection, allergy, tumor treatment, blood sugar, blood pressure, and blood lipid management [1] - 75% of the procurement demand from medical institutions has been met, indicating a strong alignment with actual needs [1] Group 2: Bidder Requirements - The bidding process has raised the qualification threshold for participating companies, requiring them to have production experience with similar types of drugs and a clean record in the last two years regarding production quality management [1] - Future supervision will involve comprehensive checks by drug regulatory authorities on selected products [1] Group 3: Competitive Landscape - The competition in this round of procurement is significantly more intense than in previous batches, with measures in place to maintain a high selection rate despite the competitive environment [1] - The average price difference for selected products has notably decreased compared to earlier batches, aided by strategies such as excluding products with a scale below 100 million and setting "anchor prices" to prevent extreme low-price impacts [1] Group 4: Participation and Impact - A total of 46,000 medical institutions participated in the reporting process, with 445 companies submitting 794 products for bidding, of which 272 companies and 453 products received proposed selection qualifications [2] - The new batch of quality and reasonably priced selected drugs is expected to be available to patients nationwide by February 2026 [2]

Core Viewpoint - The eleventh batch of national organized drug procurement has been announced, including 55 types of commonly used drugs across various fields, achieving the expected goals of stabilizing clinical use, ensuring quality, preventing excessive competition, and avoiding collusion [1][2]. Group 1: Procurement Details - The selected products in this procurement align more closely with the needs of medical institutions, with 75% of procurement requests being met [2]. - The qualification threshold for bidding enterprises has been raised, requiring experience in producing similar types of drugs and ensuring compliance with production quality management standards [2]. - The competition level in this procurement is significantly higher than in previous batches, with measures such as excluding products below 100 million yuan from procurement and setting "anchor prices" to prevent extreme low-price impacts [2]. Group 2: Regulatory and Oversight Measures - A comprehensive supervision and inspection mechanism will be implemented for selected products, ensuring adherence to quality standards [2]. - The procurement process has been standardized to prevent collusion, treating companies with related interests as a single entity to avoid price-fixing [2]. - A total of 46,000 medical institutions participated in the procurement, with 445 companies submitting bids, resulting in 272 companies having 453 products proposed for selection [2].

本次集采中选产品与医疗机构需求更加匹配，强化"稳临床"。医疗机构既可以按通用名报量，也可以按 厂牌报量，从中选结果看，医疗机构要求采购产品报量的75%得到满足。 今天（10月28日），第十一批国家组织药品集中带量采购公布中选结果。此次集采共纳入55种药品，覆 盖抗感染、抗过敏、抗肿瘤、降血糖、降血压、降血脂等领域常用药品，总体实现了"稳临床、保质 量、反内卷、防围标"预期目标。 本次集采竞争激烈程度远高于前十批集采，但通过1亿元以下规模产品不集采、设置"锚点价"防止极端 低价冲击、引入复活机制等措施，保持了较高中选率，中选产品平均价差较此前批次明显缩小。 本次集采全链条规范投标行为，坚持"防围标"。将存在股权关联、委托生产、批件转让等关联关系的企 业视同为1家，防范合谋报价。全国共4.6万家医药机构参加报量，445家企业的794个产品参与投标，其 中272家企业的453个产品获得拟中选资格。拟中选结果公示后将正式发布，预计全国患者将于2026年2 月用上新一批质优价宜的中选药。（总台央视记者 文永毅 龙晓勤） 本次集采提高了投标企业资质门槛，要求投标企业具有同类型药品生产经验，同时要求投标药品所在生 产线2年 ...

今天，第十一批国家组织药品集中带量采购公布中选结果。此次集采共纳入55种药品，覆盖抗感染、抗 过敏、抗肿瘤、降血糖、降血压、降血脂等领域常用药品，总体实现了"稳临床、保质量、反内卷、防 围标"预期目标。 （文章来源：央视新闻客户端） 本次集采中选产品与医疗机构需求更加匹配，强化"稳临床"。医疗机构既可以按通用名报量，也可以按 厂牌报量，从中选结果看，医疗机构要求采购产品报量的75%得到满足。 本次集采提高了投标企业资质门槛，要求投标企业具有同类型药品生产经验，同时要求投标药品所在生 产线2年内不存在违反药品生产质量管理规范等情况，后期药监部门将对中选产品开展全覆盖监督检 查。 本次集采竞争激烈程度远高于前十批集采，但通过1亿元以下规模产品不集采、设置"锚点价"防止极端 低价冲击、引入复活机制等措施，保持了较高中选率，中选产品平均价差较此前批次明显缩小。 本次集采全链条规范投标行为，坚持"防围标"。将存在股权关联、委托生产、批件转让等关联关系的企 业视同为1家，防范合谋报价。全国共4.6万家医药机构参加报量，445家企业的794个产品参与投标，其 中272家企业的453个产品获得拟中选资格。拟中选结果公示后将正 ...